GlassScriptPhysician profile
Jobinson Thomas
NPI 1871530055
$2,054.02
in general payments reported to CMS, 2019-2025
25 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $75.50 · 2022: $46.57 · 2023: $108 · 2024: $701 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $225.07 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $190.39 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $186.27 | 2019-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $183.85 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $133.61 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.60 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $117.99 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $114.88 | 2019 | |
| Travere Therapeutics, INC. | $114.49 | 2019-2025 | |
| Vifor Pharma, INC. | $104.51 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.21 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $84.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $51.36 | 2023-2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $49.76 | 2020-2024 | Gattex |
| Novo Nordisk INC | $37.31 | 2025 | Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $33.19 | 2024-2025 | |
| Pfizer INC. | $32.72 | 2019 | |
| Shire North American Group INC | $30.43 | 2019 | |
| Genentech USA, INC. | $29.78 | 2025 | Gazyva |
| Baxter Healthcare | $25.92 | 2024 | Renal - Pd |
| Daiichi Sankyo INC. | $18.61 | 2020 | |
| Lilly USA, LLC | $17.97 | 2024 | Jardiance |
| Amicus Therapeutics, INC. | $17.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.03 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jobinson Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.